ReEngage Therapeutics Announces Research Agreement to Accelerate Development of ACSS2 Inhibitors as Cancer Therapies
ReEngage partners with globally-recognized cancer center to study ACSS2 and its role in acetate metabolism, histone modification and DNA Damage Response HOUSTON, TX, USA, July 9, 2024 /EINPresswire.com/ -- ReEngage Therapeutics, a biotech company …